- Conditions
- Obsessive-Compulsive Disorder
- Interventions
- Troriluzole, Placebo
- Drug
- Lead sponsor
- Biohaven Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 589 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Culver City, California • La Jolla, California + 45 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–14
of 14
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Lymphoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Cancer, Recurrent Bladder Carcinoma, Recurrent Classical Hodgkin Lymphoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Renal Cell Carcinoma, Stage III Bladder Cancer, Stage III Lymphoma, Stage III Non-Small Cell Lung Cancer AJCC v7, Stage III Renal Cell Cancer, Stage III Skin Melanoma, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Skin Melanoma, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Bladder Cancer, Stage IV Lymphoma, Stage IV Non-Small Cell Lung Cancer AJCC v7, Stage IV Renal Cell Cancer, Stage IV Skin Melanoma, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Unresectable Head and Neck Squamous Cell Carcinoma, Unresectable Solid Neoplasm
- Interventions
- Enzyme Inhibitor Therapy, Laboratory Biomarker Analysis, Nivolumab, Pembrolizumab
- Drug · Other · Biological
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Melanoma, Metastatic Melanoma
- Interventions
- Ipilimumab, Nivolumab, Troriluzole, Placebo
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Obsessive Compulsive Disorder
- Interventions
- Troriluzole (BHV-4157)
- Drug
- Lead sponsor
- Biohaven Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 772 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 147
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 119 more
- Conditions
- Spinocerebellar Ataxias
- Interventions
- BHV-4157
- Drug
- Lead sponsor
- Biohaven Therapeutics Ltd.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 909 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6, Spinocerebellar Ataxia Type 7, Spinocerebellar Ataxia Type 8, Spinocerebellar Ataxia Type 10
- Interventions
- troriluzole, Placebo
- Drug
- Lead sponsor
- Biohaven Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 299 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Long Beach, California • Los Angeles, California + 16 more
- Conditions
- Glioblastoma
- Interventions
- Temozolomide, Lomustine, Regorafenib, Radiation, Paxalisib, VAL-083, VT1021, Troriluzole, ADI-PEG 20, AZD1390, Tinostamustine
- Drug · Radiation · Biological
- Lead sponsor
- Global Coalition for Adaptive Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2030
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 31 more
- Conditions
- Alzheimer Disease
- Interventions
- troriluzole, Placebo oral capsule
- Drug
- Lead sponsor
- Biohaven Pharmaceuticals, Inc.
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 44
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Fullerton, California + 39 more
- Conditions
- Obsessive-Compulsive Disorder
- Interventions
- Troriluzole, Placebo
- Drug
- Lead sponsor
- Biohaven Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 426 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 57
- States / cities
- Chandler, Arizona • Little Rock, Arkansas • Garden Grove, California + 52 more
- Conditions
- Obsessive-Compulsive Disorder
- Interventions
- Troriluzole, Placebo
- Drug
- Lead sponsor
- Biohaven Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 456 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 73
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Bellflower, California + 62 more
- Conditions
- Spinocerebellar Ataxias, Spinocerebellar Ataxia Genotype Type 1, Spinocerebellar Ataxia Genotype Type 2, Spinocerebellar Ataxia Genotype Type 3, Spinocerebellar Ataxia Genotype Type 6, Spinocerebellar Ataxia Genotype Type 7, Spinocerebellar Ataxia Genotype Type 8, Spinocerebellar Ataxia Genotype Type 10
- Interventions
- Troriluzole, Placebo
- Drug
- Lead sponsor
- Biohaven Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Long Beach, California • Los Angeles, California + 13 more
- Conditions
- Generalized Anxiety Disorder
- Interventions
- Troriluzole, Placebo
- Drug
- Lead sponsor
- Biohaven Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 881 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 53
- States / cities
- Little Rock, Arkansas • Colton, California • Encino, California + 48 more
- Conditions
- Methamphetamine Use Disorder
- Interventions
- Placebo, Methamphetamine
- Drug
- Lead sponsor
- William Stoops
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Glioblastoma, Recurrent Glioblastoma, Brain Tumor
- Interventions
- Troriluzole
- Drug
- Lead sponsor
- Ugonma Chukwueke
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts